Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Endogenous urotensin II selectively modulates erectile function through eNOS.
Bianca Rd, Mitidieri E, Fusco F, D'Aiuto E, Grieco P, Novellino E, Imbimbo C, Mirone V, Cirino G, Sorrentino R. Bianca Rd, et al. Among authors: d aiuto e. PLoS One. 2012;7(2):e31019. doi: 10.1371/journal.pone.0031019. Epub 2012 Feb 2. PLoS One. 2012. Retraction in: PLoS One. 2019 Sep 6;14(9):e0222415. doi: 10.1371/journal.pone.0222415 PMID: 22319601 Free PMC article. Retracted.
RETRACTED: Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors.
Morgillo F, D'Aiuto E, Troiani T, Martinelli E, Cascone T, De Palma R, Orditura M, De Vita F, Ciardiello F. Morgillo F, et al. Lung Cancer. 2011 Mar;71(3):283-90. doi: 10.1016/j.lungcan.2010.06.005. Lung Cancer. 2011. Retraction in: Lung Cancer. 2023 Jul;181:107226. doi: 10.1016/j.lungcan.2023.107226 PMID: 20619923 Retracted.
Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines.
Morgillo F, Sasso FC, Della Corte CM, Vitagliano D, D'Aiuto E, Troiani T, Martinelli E, De Vita F, Orditura M, De Palma R, Ciardiello F. Morgillo F, et al. Among authors: d aiuto e. Clin Cancer Res. 2013 Jul 1;19(13):3508-19. doi: 10.1158/1078-0432.CCR-12-2777. Epub 2013 May 21. Clin Cancer Res. 2013. PMID: 23695170
Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells.
Troiani T, Martinelli E, Napolitano S, Vitagliano D, Ciuffreda LP, Costantino S, Morgillo F, Capasso A, Sforza V, Nappi A, De Palma R, D'Aiuto E, Berrino L, Bianco R, Ciardiello F. Troiani T, et al. Among authors: d aiuto e. Clin Cancer Res. 2013 Dec 15;19(24):6751-65. doi: 10.1158/1078-0432.CCR-13-0423. Epub 2013 Oct 11. Clin Cancer Res. 2013. PMID: 24122793
Fat: a matter of disturbance for the immune system.
Federico A, D'Aiuto E, Borriello F, Barra G, Gravina AG, Romano M, De Palma R. Federico A, et al. World J Gastroenterol. 2010 Oct 14;16(38):4762-72. doi: 10.3748/wjg.v16.i38.4762. World J Gastroenterol. 2010. PMID: 20939104 Free PMC article. Review.
Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
Martinelli E, Troiani T, D'Aiuto E, Morgillo F, Vitagliano D, Capasso A, Costantino S, Ciuffreda LP, Merolla F, Vecchione L, De Vriendt V, Tejpar S, Nappi A, Sforza V, Martini G, Berrino L, De Palma R, Ciardiello F. Martinelli E, et al. Among authors: d aiuto e. Int J Cancer. 2013 Nov;133(9):2089-101. doi: 10.1002/ijc.28236. Epub 2013 May 29. Int J Cancer. 2013. PMID: 23629727
15 results